Colorectal cancer. Recent developments and continuing controversies

Abstract

In the last 2 years, much progress has been made in colorectal cancer research. Many of the findings, especially those involving adjuvant therapy, have important clinical applications. For example, fluorouracil (5-FU) (Adrucil) combined with levamisole hydrochloride (Ergamisol) is now recommended as adjuvant therapy for patients with Dukes' stage C (III) disease. Some aspects of colorectal cancer remain controversial, particularly screening recommendations and monitoring of carcinoembryonic antigen levels.